September 24, 2015
Novartis Pharma said on September 18 that it has filed an application seeking an additional indication for Afinitor (everolimus) for the treatment of neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin. Afinitor, Japan’s first oral mTOR inhibitor approved as...read more